alli: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-01	60 CAPSULE in 1 BOTTLE (0135-0461-01)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-02	90 CAPSULE in 1 BOTTLE (0135-0461-02)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-03	120 CAPSULE in 1 BOTTLE (0135-0461-03)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-05	120 CAPSULE in 1 BOTTLE (0135-0461-05)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-06	170 CAPSULE in 1 BOTTLE (0135-0461-06)	2007-02-07
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 27, 2025

Introduction

Alirocumab (brand name: ALLI) is a monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi, approved by the U.S. Food and Drug Administration (FDA) in 2015 to treat heterozygous familial hypercholesterolemia and clinical atherosclerotic cardiovascular disease. As a PCSK9 inhibitor, ALLI plays a pivotal role in cholesterol management, offering an alternative for patients unable to achieve LDL cholesterol targets through traditional therapies.

The manufacturing and supply chain ecosystem for ALLI hinges on sourcing high-quality biologic raw materials, sophisticated bioprocessing facilities, and regulated distribution channels. Ensuring a reliable supply chain is vital given the drug's importance in cardiovascular therapy and its relatively complex production process.

Manufacturers and Suppliers of Active Pharmaceutical Ingredient (API)

1. Proprietary Production by Regeneron and Sanofi

Alli is a biologic monoclonal antibody produced predominantly by the original developers:

Regeneron Pharmaceuticals Inc. – Located in Tarrytown, New York, Regeneron’s manufacturing facilities are GMP-compliant and equipped to produce monoclonal antibodies at scale.
Sanofi – With manufacturing sites globally, including major biologics production facilities in France and the U.S., Sanofi is responsible for mass production and distribution.

Both companies maintain integrated supply chains for their biologics, ensuring high-quality API production, often involving in-house sourcing of cell lines, raw materials, and purification systems.

2. Raw Material Suppliers

The manufacturing of monoclonal antibodies like ALLI involves complex bioprocessing, relying on critical raw materials:

Cell Culture Media Components: Suppliers such as Thermo Fisher Scientific, Sartorius, and Corning supply cell culture media, reagents, and sera necessary for cultivation of CHO (Chinese Hamster Ovary) cells used in antibody production.
Bioreactors and Fermentation Equipment: Suppliers include GE Healthcare and Sartorius, providing bioreactors and purification systems.
Single-use Systems (SUS): These disposable bioprocessing components facilitate sterile operations and are procured from Pall Corporation or Thermo Fisher.
Chemicals and Buffers: Suppliers like Sigma-Aldrich supply critical buffers and chemicals used in downstream purification steps.

3. Monoclonal Antibody (mAb) Raw Materials

Key raw materials include Protein A chromatography resins for antibody purification, supplied by:

Cytiva (formerly GE Healthcare Life Sciences) – A leading provider of Protein A resins used during downstream processing.
Repligen – Supplies specialized chromatography media.

Manufacturing and Distribution Landscape

1. Contract Manufacturing Organizations (CMOs)

While Regeneron and Sanofi lead direct production, several CMOs support the supply chain, particularly:

Boenning & Scattergood – Historically involved in biotech manufacturing support.
Samsung Biologics – Offers large-scale biologics manufacturing services, though direct supply of ALLI is not publicly confirmed.
CobinBio and Bio Transplant – Smaller players providing fill-finish and formulation services.

2. Distribution Partners

Post-manufacturing, ALLI is distributed globally through Sanofi’s extensive network. Distribution channels are regulated and follow cold-chain logistics protocols, ensuring product integrity for biologics.

Major pharmaceutical logistics firms include:

AmerisourceBergen
McKesson
UPS Healthcare Logistics

These companies maintain temperature-controlled shipping infrastructures compliant with international standards.

Regulatory and Quality Considerations

Suppliers are subject to strict regulatory oversight by agencies such as the FDA, EMA (European Medicines Agency), and other national agencies. Manufacturers must adhere to Good Manufacturing Practice (GMP) standards, ensuring consistent quality, purity, and potency in ALLI production.

1. Quality Assurance (QA)

GMP Certification: Key suppliers and manufacturers hold GMP certifications, crucial for biologic manufacturing.
Batch Testing: Suppliers conduct extensive testing for sterility, endotoxins, and bioactivity before product release.

2. Supply Chain Resilience

The COVID-19 pandemic underscored the importance of a resilient supply chain. Sanofi and Regeneron, along with raw material suppliers, have diversified sourcing strategies and strategic stockpiles to mitigate disruptions.

Key Challenges in the Supply Chain

Complex Manufacturing Processes: Monoclonal antibody production is technically challenging, requiring precise bioreactor control and downstream processing.
Raw Material Scarcity: Global demand for bioprocess raw materials can cause supply constraints.
Cold Chain Logistics: Maintaining strict temperature controls during distribution is critical for product efficacy.
Regulatory Variability: Compliance standards differ across regions, necessitating customized manufacturing and distribution strategies.

Future Outlook and Innovations

Emerging technologies such as continuous bioprocessing, single-use bioreactors, and advanced cell line engineering aim to optimize ALLI supply. Additionally, collaborations with global CDMOs and diversification of raw material sources will improve supply resilience.

The trend towards biosimilars and newer PCSK9 inhibitors may influence the supply landscape, emphasizing the need for scalable, flexible manufacturing systems. As the biologics market expands, suppliers that invest in advanced manufacturing capacity and supply chain transparency will be better positioned to meet global demand.

Key Takeaways

The primary manufacturers of ALLI are Regeneron and Sanofi, with raw materials sourced from leading bioprocess suppliers such as Thermo Fisher, Sartorius, and Cytiva.
The complexity of biologic manufacturing necessitates reliance on specialized raw materials, advanced bioreactor technology, and strict regulatory compliance.
Distribution relies heavily on cold-chain logistics, with global pharmaceutical logistics firms ensuring product integrity.
Supply chain resilience is increasingly critical, with diversified sourcing and technological innovation addressing recent disruptions.
The future of ALLI supply hinges on advances in bioprocessing, raw material diversification, and integration with global manufacturing networks.

FAQs

1. Who are the main raw material suppliers for ALLI?
Suppliers like Thermo Fisher Scientific, Sartorius, Corning, and Cytiva provide crucial raw materials such as cell culture media, chromatography resins, and bioprocessing equipment necessary for ALLI production.

2. Do third-party contract manufacturing organizations produce ALLI?
While Regeneron and Sanofi primarily handle manufacturing, some CMO partners may support fill-finish and formulation processes, though specific partnerships for ALLI are not publicly disclosed.

3. How is the supply chain for ALLI managed globally?
Manufacturers and distributors coordinate via GMP-compliant facilities, cold chain logistics, and regulatory adherence, leveraging global logistics providers to ensure drug availability.

4. What are the key challenges in the supply chain of ALLI?
Biologic complexity, raw material shortages, cold chain logistics, and regulatory compliance pose ongoing risks, necessitating strategic planning and supply chain diversification.

5. Are biosimilars affecting the supply of ALLI?
Biosimilar versions of PCSK9 inhibitors may influence market dynamics, but currently, ALLI remains a key biologic with a well-established supply chain supported by robust manufacturing capacity.

References

[1] FDA. Alirocumab (brand name: Praluent). U.S. Food and Drug Administration, 2015.
[2] Sanofi. Annual Report 2022. Sanofi.
[3] Regeneron Pharmaceuticals. Product Pipeline and Manufacturing Insights. 2022.
[4] Cytiva. Bioprocessing Raw Materials & Resin Supplies. 2023.
[5] Sartorius. Bioprocess Solutions for Monoclonal Antibody Manufacturing. 2023.

Suppliers and packagers for alli

alli

Suppliers for the Pharmaceutical Drug: ALLI (Alirocumab)